Viking Therapeutics, Inc.

NASDAQ (USD): Viking Therapeutics, Inc. (VKTX)

Last Price

43.41

Today's Change

+1.92 (4.62%)

Day's Change

41.97 - 45.00

Trading Volume

6,321,677

Overview

Market Cap

4 Billion

Shares Outstanding

111 Million

Avg Volume

4,245,411

Avg Price (50 Days)

58.21

Avg Price (200 Days)

61.87

PE Ratio

-45.82

EPS

-0.94

Earnings Announcement

05-Feb-2025

Previous Close

41.49

Open

44.18

Day's Range

41.975 - 45.0

Year Range

17.23 - 99.41

Trading Volume

6,333,614

Price Change Highlight

1 Day Change

3.81%

5 Day Change

-10.25%

1 Month Change

-16.42%

3 Month Change

-38.88%

6 Month Change

-14.59%

Ytd Change

135.61%

1 Year Change

144.44%

3 Year Change

770.10%

5 Year Change

454.31%

10 Year Change

438.38%

Max Change

438.38%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment